Ind-Swift Laboratories Limited (INDSWFTLAB.BO)
INR 106.0
(-2.0%)
INR 106.0
(-2.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 2.12 Billion INR | -17.96% |
| 2022 | 2.58 Billion INR | -18.37% |
| 2021 | 3.17 Billion INR | 20.08% |
| 2020 | 2.64 Billion INR | 11.51% |
| 2019 | 2.36 Billion INR | -0.56% |
| 2018 | 2.38 Billion INR | 4.03% |
| 2017 | 2.28 Billion INR | 8.6% |
| 2016 | 2.1 Billion INR | -1.62% |
| 2015 | 2.14 Billion INR | 25.93% |
| 2014 | 1.7 Billion INR | 10.06% |
| 2013 | 1.54 Billion INR | -1.42% |
| 2012 | 1.56 Billion INR | 45.55% |
| 2011 | 1.07 Billion INR | -11.73% |
| 2010 | 1.22 Billion INR | 57.09% |
| 2009 | 777.13 Million INR | 19.57% |
| 2008 | 649.91 Million INR | 25.54% |
| 2007 | 517.68 Million INR | 17.02% |
| 2006 | 442.39 Million INR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 95.09 Million INR | -87.85% |
| 2023 Q1 | 1.01 Billion INR | 403.32% |
| 2023 FY | 2.12 Billion INR | -17.96% |
| 2023 Q4 | 782.48 Million INR | -16.71% |
| 2023 Q3 | 939.44 Million INR | 1.29% |
| 2023 Q2 | 927.52 Million INR | -8.76% |
| 2022 Q1 | 994.48 Million INR | 83.92% |
| 2022 FY | 2.58 Billion INR | -18.37% |
| 2022 Q4 | -335.16 Million INR | -136.54% |
| 2022 Q3 | 917.23 Million INR | -9.43% |
| 2022 Q2 | 1.01 Billion INR | 1.83% |
| 2021 Q1 | 857.74 Million INR | 2337.63% |
| 2021 Q4 | 540.71 Million INR | -48.42% |
| 2021 Q3 | 1.04 Billion INR | 18.23% |
| 2021 Q2 | 886.7 Million INR | 3.38% |
| 2021 FY | 3.17 Billion INR | 20.08% |
| 2020 FY | 2.64 Billion INR | 11.51% |
| 2020 Q2 | 928.41 Million INR | 21.95% |
| 2020 Q3 | 850.1 Million INR | -8.43% |
| 2020 Q4 | -38.33 Million INR | -104.51% |
| 2020 Q1 | 761.31 Million INR | 757.8% |
| 2019 Q4 | -115.73 Million INR | -113.77% |
| 2019 FY | 2.36 Billion INR | -0.56% |
| 2019 Q3 | 840.56 Million INR | 3.18% |
| 2019 Q2 | 814.66 Million INR | 2.82% |
| 2019 Q1 | 792.33 Million INR | 597.07% |
| 2018 Q2 | 809.76 Million INR | -11.35% |
| 2018 FY | 2.38 Billion INR | 4.03% |
| 2018 Q4 | -159.4 Million INR | -119.76% |
| 2018 Q1 | 913.43 Million INR | 0.0% |
| 2018 Q3 | 806.79 Million INR | -0.37% |
| 2017 FY | 2.28 Billion INR | 8.6% |
| 2016 FY | 2.1 Billion INR | -1.62% |
| 2015 FY | 2.14 Billion INR | 25.93% |
| 2014 FY | 1.7 Billion INR | 10.06% |
| 2013 FY | 1.54 Billion INR | -1.42% |
| 2012 Q2 | 355.25 Million INR | -18.01% |
| 2012 FY | 1.56 Billion INR | 45.55% |
| 2012 Q3 | 575.42 Million INR | 61.97% |
| 2012 Q1 | 433.31 Million INR | 0.0% |
| 2012 Q4 | 214.49 Million INR | -62.72% |
| 2011 FY | 1.07 Billion INR | -11.73% |
| 2010 FY | 1.22 Billion INR | 57.09% |
| 2009 FY | 777.13 Million INR | 19.57% |
| 2008 FY | 649.91 Million INR | 25.54% |
| 2007 FY | 517.68 Million INR | 17.02% |
| 2006 FY | 442.39 Million INR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Ajanta Pharma Limited | 30.46 Billion INR | 93.027% |
| Amrutanjan Health Care Limited | 1.09 Billion INR | -93.285% |
| Sigachi Industries Limited | 579.88 Million INR | -266.31% |
| Bal Pharma Limited | 389.89 Million INR | -444.816% |
| Medico Remedies Limited | 161.84 Million INR | -1212.489% |
| Lasa Supergenerics Limited | 291.17 Million INR | -629.524% |
| Venus Remedies Limited | 1.91 Billion INR | -10.849% |
| Sun Pharma Advanced Research Company Limited | 3.07 Billion INR | 30.961% |
| Alpa Laboratories Limited | 156.14 Million INR | -1260.375% |
| Nectar Lifesciences Limited | 625.55 Million INR | -239.571% |
| Shilpa Medicare Limited | 2.18 Billion INR | 2.587% |
| Aarti Drugs Limited | 1.16 Billion INR | -81.946% |
| Lupin Limited | 95.67 Billion INR | 97.78% |
| Aurobindo Pharma Limited | 39.23 Billion INR | 94.586% |
| Zydus Lifesciences Limited | 43.17 Billion INR | 95.08% |
| Windlas Biotech Limited | 1 Billion INR | -111.045% |
| Suven Life Sciences Limited | 109.75 Million INR | -1835.475% |
| Eris Lifesciences Limited | 4.94 Billion INR | 57.026% |
| Valiant Laboratories Limited | 36.28 Million INR | -5753.52% |
| J. B. Chemicals & Pharmaceuticals Limited | 8.41 Billion INR | 74.763% |
| Solara Active Pharma Sciences Limited | 4.57 Billion INR | 53.617% |
| Ipca Laboratories Limited | 13.91 Billion INR | 84.734% |
| Bliss GVS Pharma Limited | 1.41 Billion INR | -49.672% |
| Achyut Healthcare Limited | 1.6 Million INR | -131918.894% |
| Sun Pharmaceutical Industries Limited | 154.18 Billion INR | 98.622% |
| Bajaj HealthCare Limited | 985.34 Million INR | -115.578% |
| RPG Life Sciences Limited | 1.63 Billion INR | -29.88% |
| Mankind Pharma Limited | 23.15 Billion INR | 90.825% |
| Laurus Labs Limited | 3.01 Billion INR | 29.448% |
| Piramal Pharma Limited | 19.91 Billion INR | 89.333% |
| Syncom Formulations (India) Limited | 942.39 Million INR | -125.402% |
| Torrent Pharmaceuticals Limited | 21.42 Billion INR | 90.084% |
| Alembic Pharmaceuticals Limited | 15.86 Billion INR | 86.615% |
| Glenmark Pharmaceuticals Limited | 67.56 Billion INR | 96.856% |
| Unichem Laboratories Limited | 6.72 Billion INR | 68.418% |
| Sequent Scientific Limited | 2.9 Billion INR | 26.798% |
| Novartis India Limited | 470.1 Million INR | -351.858% |
| Wanbury Limited | 1.16 Billion INR | -82.973% |
| Suven Pharmaceuticals Limited | 1.4 Billion INR | -51.426% |
| Wockhardt Limited | 6.4 Billion INR | 66.81% |
| Themis Medicare Limited | 782.85 Million INR | -171.338% |
| Jagsonpal Pharmaceuticals Limited | 773.41 Million INR | -174.652% |
| Jubilant Pharmova Limited | 14.45 Billion INR | 85.304% |
| Glenmark Life Sciences Limited | 11.64 Billion INR | 81.752% |
| Dr. Reddy's Laboratories Limited | 95.87 Billion INR | 97.784% |
| Divi's Laboratories Limited | 14.17 Billion INR | 85.009% |
| NATCO Pharma Limited | 10.05 Billion INR | 78.881% |
| Gufic Biosciences Limited | 1.07 Billion INR | -97.101% |
| IOL Chemicals and Pharmaceuticals Limited | 1.09 Billion INR | -93.319% |
| Ind-Swift Limited | 946.56 Million INR | -124.409% |
| Procter & Gamble Health Limited | 2.99 Billion INR | 29.085% |
| FDC Limited | 5.34 Billion INR | 60.285% |
| Krebs Biochemicals & Industries Limited | 46.15 Million INR | -4502.184% |
| Granules India Limited | 7.18 Billion INR | 70.425% |
| Medicamen Biotech Limited | 335.16 Million INR | -533.769% |
| Alkem Laboratories Limited | 32.83 Billion INR | 93.531% |
| AstraZeneca Pharma India Limited | 2.6 Billion INR | 18.313% |
| Biofil Chemicals and Pharmaceuticals Limited | 16.2 Million INR | -13004.401% |
| Brooks Laboratories Limited | 51.18 Million INR | -4050.418% |
| Megasoft Limited | 49.52 Million INR | -4188.855% |
| ZIM Laboratories Limited | 1.01 Billion INR | -109.68% |
| Strides Pharma Science Limited | 9.16 Billion INR | 76.816% |
| Neuland Laboratories Limited | 2.92 Billion INR | 27.496% |
| Morepen Laboratories Limited | 1.98 Billion INR | -6.88% |
| Hikal Limited | 2.48 Billion INR | 14.566% |
| Indoco Remedies Limited | 4.74 Billion INR | 55.269% |
| Aarti Pharmalabs Limited | 3.07 Billion INR | 30.907% |
| Kilitch Drugs (India) Limited | 412.42 Million INR | -415.045% |
| Mangalam Drugs & Organics Limited | 676.14 Million INR | -214.16% |
| Hester Biosciences Limited | 908.84 Million INR | -133.725% |